Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
38 hedge funds and large institutions have $4.58M invested in Oncternal Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 14 closing their positions.
63% more capital invested
Capital invested by funds: $2.81M → $4.58M (+$1.77M)
24% less funds holding
Funds holding: 50 → 38 (-12)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
79% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$147K |
| 2 |
PPW
Pasadena Private Wealth
Pasadena,
California
|
+$79.7K |
| 3 |
Morgan Stanley
New York
|
+$31.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$19.5K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$13.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$144K |
| 2 |
QPW
Quantum Private Wealth
Tampa,
Florida
|
-$138K |
| 3 |
BJL
Brighton Jones LLC
Seattle,
Washington
|
-$102K |
| 4 |
Corient Private Wealth
Miami,
Florida
|
-$27.5K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
-$16.2K |
ONCT Hedge Fund Activity: Q4 2023 in Review
38 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2023, worth a combined $4.58M — up 63% from $2.81M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ONCT and 3 opened new positions — a net loss of 11 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Millennium Management, adding an estimated $147K. The largest seller was Geode Capital Management, exiting entirely with an estimated $144K sold.
- 38 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2023, down from 50 in Q3 2023.
- Funds reported $4.58M of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2023, up 63% quarter-over-quarter.
- 3 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2023 and 14 closed out, a net change of -11 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2023 was Millennium Management, an estimated $147K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2023 was Geode Capital Management, an estimated $144K sold.
Based on aggregated 13F filings for Q4 2023.